These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10991665)

  • 1. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments.
    Jenner P
    J Neurol; 2000 Apr; 247 Suppl 2():II43-50. PubMed ID: 10991665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
    Jenner P
    Mov Disord; 2008; 23 Suppl 3():S585-98. PubMed ID: 18781676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD.
    Jenner P
    Neurology; 2003 Dec; 61(11 Suppl 6):S32-8. PubMed ID: 14663007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates.
    Jenner P
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S90-9; discussion S99-104. PubMed ID: 10762136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of dopamine agonists in the treatment of Parkinson's disease.
    Jenner P
    Neurology; 2002 Feb; 58(4 Suppl 1):S1-8. PubMed ID: 11909980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease.
    Jenner P
    Parkinsonism Relat Disord; 2003 Jan; 9(3):131-7. PubMed ID: 12573867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications.
    Jenner P
    Neurology; 2003 Sep; 61(6 Suppl 3):S4-11. PubMed ID: 14504374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
    Iravani MM; Costa S; Jackson MJ; Tel BC; Cannizzaro C; Pearce RK; Jenner P
    Eur J Neurosci; 2001 Feb; 13(3):597-608. PubMed ID: 11168568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex.
    Calon F; Goulet M; Blanchet PJ; Martel JC; Piercey MF; Bédard PJ; Di Paolo T
    Brain Res; 1995 May; 680(1-2):43-52. PubMed ID: 7663983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA.
    Zeng BY; Pearce RK; MacKenzie GM; Jenner P
    Eur J Neurosci; 2000 Mar; 12(3):1096-104. PubMed ID: 10762340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Huot P; Johnston TH; Koprich JB; Aman A; Fox SH; Brotchie JM
    J Pharmacol Exp Ther; 2012 Aug; 342(2):576-85. PubMed ID: 22619253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
    Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ
    Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
    Maratos EC; Jackson MJ; Pearce RK; Cannizzaro C; Jenner P
    Exp Neurol; 2003 Jan; 179(1):90-102. PubMed ID: 12504871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies.
    Sharma S; Singh S; Sharma V; Singh VP; Deshmukh R
    Biomed Pharmacother; 2015 Mar; 70():283-93. PubMed ID: 25776513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
    Smith LA; Tel BC; Jackson MJ; Hansard MJ; Braceras R; Bonhomme C; Chezaubernard C; Del Signore S; Rose S; Jenner P
    Mov Disord; 2002 Sep; 17(5):887-901. PubMed ID: 12360537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.
    Henry B; Duty S; Fox SH; Crossman AR; Brotchie JM
    Exp Neurol; 2003 Oct; 183(2):458-68. PubMed ID: 14552886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
    Jenner P
    Neurology; 2004 Jan; 62(1 Suppl 1):S47-55. PubMed ID: 14718680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets.
    Johnston LC; Jackson MJ; Rose S; McCreary AC; Jenner P
    Mov Disord; 2010 Oct; 25(13):2059-66. PubMed ID: 20721904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
    Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
    Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
    Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.